Compare · ABT vs GNLX
ABT vs GNLX
Side-by-side comparison of Abbott Laboratories (ABT) and Genelux Corporation (GNLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and GNLX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $181.14B, about 1614.3x GNLX ($112.2M).
- ABT has hit the wire 13 times in the past 4 weeks while GNLX has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 6 for GNLX).
- Company
- Abbott Laboratories
- Genelux Corporation
- Price
- -
- -
- Market cap
- $181.14B
- $112.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2023
- News (4w)
- 13
- 0
- Recent ratings
- 25
- 6
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
- Barclays initiated coverage on Abbott Labs with a new price target
- Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- SEC Form 4 filed by Director Roman Michael F
- Abbott Labs upgraded by Rothschild & Co Redburn with a new price target
- Abbott hosts conference call for third-quarter earnings
Latest GNLX
- Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
- President and CEO Zindrick Thomas sold $91,899 worth of shares (34,463 units at $2.67), decreasing direct ownership by 3% to 1,226,427 units (SEC Form 4)
- Chief Scientific Officer Yu Yong sold $26,658 worth of shares (9,683 units at $2.75), decreasing direct ownership by 4% to 258,688 units (SEC Form 4)
- Chief Technical Officer Cappello Joseph sold $28,112 worth of shares (10,257 units at $2.74), decreasing direct ownership by 3% to 318,480 units (SEC Form 4)
- Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
- SEC Form 10-Q filed by Genelux Corporation
- Chief Technical Officer Cappello Joseph sold $1,924 worth of shares (653 units at $2.95), decreasing direct ownership by 0.20% to 328,737 units (SEC Form 4)
- President and CEO Zindrick Thomas sold $8,905 worth of shares (3,023 units at $2.95), decreasing direct ownership by 0.24% to 1,260,890 units (SEC Form 4)
- Chief Scientific Officer Yu Yong sold $1,922 worth of shares (653 units at $2.94), decreasing direct ownership by 0.24% to 268,371 units (SEC Form 4)
- Attovia Therapeutics Appoints John W. Smither to Board of Directors